This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Neovastat

AEterna Zentaris, Inc.

Drug Names(s): AE-941

Description: Neovastat is a standardized liquid extract derivedfrom cartilage, and is unique from other antiangiogenesis therapies since it possesses multiple mechanisms of action. In addition,Neovastat has also demonstrated antitumor and antimetastatic properties.

Deal Structure: Pfizer and Hospira
In February 2015, Pfizer and Hospira announced that they have entered into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive upon closing, accretive by $0.10 - $0.12 per share for the first full year following the close of the transaction with additional accretion anticipated thereafter. Pfizer expects to finance the transaction through a combination of existing cash and new debt, with approximately two-thirds of the value financed from cash and one-third from debt.

In September 2015, Pfizer completed its acquisition of Hospira.

Partners: Grupo Ferrer Internacional, S.A. medac GmbH Pfizer Inc.


Neovastat News

Pink Sheet Shark cartilage

Pink Sheet Shark cartilage


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug